{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-275466","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.132573+00:00","generated_at":"2026-06-22T14:59:36.537104+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology","bullets":["David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.","Dr. Ryan brings over 20 years of oncology experience; Clinical Director at MGH Cancer Center since 2012.","Received option grant with $250,000 fair value, vesting one-third annually over three years.","Ansbert Gadicke, M.D. resigned as director effective Nov 1, 2022; no disagreement with Company.","Dr. Ryan appointed to Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-275466","json":"https://secwatch.observer/filing/0001193125-22-275466.json","markdown":"https://secwatch.observer/filing/0001193125-22-275466.md","text":"https://secwatch.observer/filing/0001193125-22-275466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/d332832d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:59:36.537104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14eb6323de","claim":"Ansbert Gadicke resigned as director at Cullinan Therapeutics, Inc..","evidence_excerpt":"Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"9c3decba9f","claim":"David P. Ryan was appointed as Class II director at Cullinan Therapeutics, Inc..","evidence_excerpt":"appointed David P. Ryan, M.D. as a Class II director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}